SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Psychiatry ABPN Question Bank
Activity/Course #:
: BVPSY
Cost:
: $599.00
Release/Start Date:
: Oct 21 2016
Expiration Date:
: Dec 31 2018
Topics:
: Board Review/Prep
Target Audience:
: Psychiatrists
Format:
: Board Review Prep Course
Estimated Time To Complete CME Activity:
: 40.0 hours
Credit(s):
: 40.0 AMA PRA Category I Credit(s)
Hardware/Software Requirements:
Prepare for the American Board of Psychiatry and Neurology (ABPN) MOC Exam and fulfill MOC Requirements with over 1,600 Psychiatry Board Exam Questions. Earn up to 40.00 AMA PRA Category 1 CME Credit(s)™ and 40 ABPN MOC points, including the hard to find Self Assessment (SA) points, quickly and easily with just one activity.

 

Features

  • One-year access to over 1,600 psychiatry CME questions mapped to the Psychiatry MOC Exam

  • The most thorough and advanced Psychiatry Board Review Questions, at a fraction of the cost of board review courses
  • Updated for DSM changes per ABPN for 2015-2016
  • Complete up to 40.00 AMA PRA Category 1 CME Credit(s)™
  • Approved for 40 hours of ABPN MOC and Self Assessment Credits
  • Correct your answers as you go with evidence-based rationales for the correct answers

Developed by top faculty and practicing physicians, BoardVitals helps thousands of doctors prepare for board certification exams and complete their CME requirements. BoardVitals is trusted by leading medical institutions including Harvard, Yale, Mt. Sinai, and Duke.


"This has been hands down the easiest way to earn Psych CME hours. I prepared for my exams while knocking out the hours requirement. Great qbank!" S. Paul, MD, Child and Adolescent Psych, Florida

 
Sample Psychiatry Questions
 
Question 1
Patients taking Selegiline may test urine positive for which drug?
 
A.) benzodiazepine
B.) methamphetamine
C.) marijuana
D.) cocaine
E.) opiate
 
Answer
B.) methamphetamine
 
Explanation
The correct answer is B. Selegiline is metabolized by the body into lmethamphetamine and lamphetamine, and a package insert is meant to alert users that this is a likely side effect of being on this drug. If they test positive for the other drugs on the list, it is more likely a positive drug test. Selegiline is a substituted phenethylamine used for the treatment of earlystage Parkinson's disease, depression and dementia. In normal clinical doses it is a selective irreversible MAOB inhibitor. However, in larger doses it loses its specificity and also inhibits MAOA.
 
Reference
Joska JA and Stein DJ. “Chapter 11: Mood Disorders” in The American Psychiatric Publishing Textbook of Psychiatry, 5th Ed. Hales RE, Yudofsky SC, Gabbard GO, editors. American Psychiatric Publishing, 2011
 
This question was taken from BoardVitals Psychiatry CME Question Bank
 
Question 2
A health care provider learns from a mutual acquaintance that a former patient who was treated for opioid addiction 5 years previously has completed medical school and entered a residency program. They last saw the patient 4 years ago, at which time the patient was compliant with treatment. Which of the following is true?
 
A.) Breach confidentiality and report the health care provider to the medical board
B.) Contact the health care provider assistance program in the former patient’s state and
     reveal the history of drug abuse
C.) Without evidence that the former patient is impaired, you should not breach
     confidentiality
D.) Contact the former patient and request evidence of compliance with treatment
E.) You have a legal duty to inform a responsible authority about the former patient’s
     potential impairment
 
Answer
C.) Without evidence that the former patient is impaired, you should not breach confidentiality
 
Explanation
Correct answer: (C) Without evidence that the former patient is impaired, you should not breach confidentiality. Explanation: Although impairment may result from the use of psychoactive agents or illness, the presence of a disorder does not necessarily imply impairment. Unless a health care provider seems to be impaired now, there is no legal or ethical duty to report the health care provider based on history. Unless
there is evidence of current impairment or patient danger, a patient who is happens to be a health care provider has the same rights to confidentiality under the provider patient
relationship. When a health care provider identifies an impaired health care provider, there is a clear ethical duty to protect the patients of the impaired health care provider by reporting to an appropriate authority, although the legal responsibility to report an impaired health care provider varies among from state to state.
 
Reference
https://www.acponline.org/running_practice/ethics/manual/manual6th.htm#medicalrisk
 
This question was taken from BoardVitals Psychiatry CME Question Bank

Categories Covered in Course

Mental Retardation

Learning Disorders

Communication Disorders

Autistic Disorder

Rett's Disorder

Childhood Disintegrative Disorder

Asperger's Disorder

ADHD

Conduct Disorder

Oppositional Defiant Disorder

Feeding Disorders of Infancy/Childhood

Tic Disorders

Other Child/Adolescent Disorders

Delirium

Dementia

Amnesic Disorders

Alcohol-Related Disorders

Amphetamine-Related Disorders

Caffeine-Related Disorders

Cannabis-Related Disorders

Cocaine-Related Disorders

Hallucinogen-Related Disorders

Inhalant-Related Disorders

 

Nicotine-Related Disorders

Opioid-Related Disorders

Other Substance-Related Disorders

Schizophrenia

Schizophreniform Disorder

Schizoaffective Disorder

Delusional Disorder

Major Depression

Dysthymic Disorder

Bipolar I Disorder

Bipolar II Disorder

Cyclothymic Disorder

Other Mood Disorders

Panic Disorder and Agoraphobia

Specific Phobia

Social Phobia

OCD

PTSD

Generalized Anxiety Disorder

Acute Stress Disorder

Other Anxiety Disorders

Somatization Disorder

Conversion Disorder

 

Other Somatoform and Pain Disorders

Anorexia

Bulimia

Sleep Disorders

Basic Neuroscience and Neural Development

Other Neurological Disorders

Diagnostic Procedures in Neurology

Evaluation of Neurologic Disorders

Treatment of Neurological Disorders

Psychopharmacology-Antipsychotics

Psychopharmacology-Antidepressants

Psychopharmacology-Anxiolytics

Psychopharmacology-Sleep/Wake Medications

Psychopharmacology-ADHD Medications

Psychopharmacology-Dementia Medications

Psychopharmacology-Substance Abuse Medications

Psychopharmacology-Somatoform and Pain Medications

Complementary and Alternative Therapies


Sponsored and Certified By
Interstate Postgraduate Medical Association
Accreditation Designation Statement
The IPMA is accredited by the ACCME to provide continuing medical education for physicians. The Interstate Postgraduate Medical Association designates this Internet Enduring Material for a maximum of 40 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Further Psychiatry CME info found here.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Commercial Support
No commercial support for this activity.